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140 Poster Session-IIcells peak around day130. Median number of NK cells on day130 was
420/ml (range; 161–1167) in CD3/CD19 depleted group compared to
234/ml (range; 9- 644) in the CD341 selected group. On day1100 the
median number of NK cells/ml were 210 (range; 25–350) versus 68
(range; 50–123) (p 5 0.02) respectively. Recipient NK cell phenotype
and function were analyzed and compared to donor NK cells. We ob-
served anincrease of CD56bright NKcell subset in both groups. The me-
dian percentage of CD56bright cells among NK cells in peripheral blood
was 21.4% (range; 7.8–46%) for patients receiving a CD3/CD19 de-
pleted graft and 33% (range; 17.7–62%) (p\0.05). On day 1100 the
median percentage of CD56bright cells were 13.4% (range; 4.6–22%)
and 37.5% (range; 22.5–61%) (p 5 0.001) respectively. Patients NK
cell cytotoxicity was lower at time of engraftment (3%) compared to
their respective donors (20%) (p\0.05) and reached the donor values
by day1100. We observed a diminished KIR expression on KIR2DL1,
KIR2DL2 and especially in KIR3DL1. We also observed a lower ex-
pression of activating receptors NKp30 and NKp44 and in the activat-
ing C-type lectin receptor NKG2D. The expression of CD69 was also
lower compared with their respective donors. These results suggest that
NK repertoire early after unrelated transplantation is determined by the
imbalance between CD56bright and NK CD56dim subsets. This imbal-
ance is higher in patients undergoing unrelated transplantation using
CD341 selected graft compared to those patients receiving a CD3/
CD19 depleted graft.
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The regulatory function of CD41CD25highCD127dim T-cells
(Tregs) has been associated with the risk of disease relapse, with
GVHD in the allogeneic HSCT setting, and with the immunomod-
ulatory capacity of autologous HSCT for autoimmune disorders.
Despite their potentially important role in HSCT, their patterns
of immune reconstitution postransplant remain unknown. In this
study, we have analyzed the kynetics of immune reconstitution of
Tregs in 42 adult (median age 56, 28–74), 27 male and 15 female, re-
cipients of an autologous peripheral blood HSCT following condi-
tioning with Melphalan-200 (multiple myeloma, n 5 31) or BEAM
(NHL, n 5 11) from May 2006 to October 2007. Peripheral blood
samples were prospectively collected prior to and at various time
points after HSCT. Tregs were defined by their immunophenotype
(CD31CD41CD25highCD127dim) and are expressed as a percentage
of total CD41 T-cells. FoxP3 and CTLA4 mRNA expression was
performed in duplicate with 500ng mRNA in a LightCycler with
TaqMan probes, and is presented in arbitrary units as a normalized
ratio to the level of expression of b2-microglobulin. Immune recon-
stitution of Tregs occurs unexpectedly early after HSCT. The per-
centage of Tregs triples the pretransplant baseline level at only
two weeks postransplant (6.35% vs 2.17%; p\0.001; table 1). Tregs
remain high at day190 when lymphocyte count recovery starts tak-
ing place. The level of early Tregs expansion at day 114 showed
a strong correlation with the baseline Tregs level prior to HSCT
(r 5 0.74; p 5 0.029). Markers of Tregs regulatory function such
as FoxP3 (10.32 vs 3.0; p 5 0.003) or CTLA4 (13.21 vs 6.35; p 5
0.082) outline a profile of mRNA expression that mirrors the early
expansion of Tregs, providing additional evidence of a true func-
tional immune reconstitution of Tregs early after SCT.
Table 1
Time CD31 Tregs FoxP3 CTLA4
Points Lymph (10e9/L) (% of CD41) (b2-ratio) (b2-ratio)Pre-HSCT 1.46 6 0.67 2.17 6 0.96 3.00 6 4.78 6.35 6 6.64
Day 114 1.04 6 1.28 6.35 6 1.45 10.32 6 9.56 13.21 6 13.65
Day 190 2.07 6 1.15 5.87 6 2.13 2.42 6 1.85 6.22 6 4.49
ANOVA 0.061 0.001 0.003 0.082values in table are mean6S.D.This is the first study to analyze the kynetics of immune recovery
of Tregs after autologous HSCT, and it shows that it takes place as
early as two weeks into the procedure. Although FoxP3 and CD25-
expression can be induced in non-regulatory T-cells by early allor-
reactive phenomena after allogeneic SCT, this should not be a con-
founding factor or compromise the analysis in the autologous
setting. Understanding the early kynetics of Tregs postransplant re-
constitution offers potential targets for immunomodulatory thera-
peutic strategies at the early phase of Tregs expansion
postransplant or even at their baseline level which correlates with
their subsequent expansion.391
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NK cells are characterized by absent CD3 but expression of
CD56dim (90%, cytotoxic) and CD56bright (10%, mediator). NK
cells may contribute to the immaturity in cord blood innate and
adaptive immunity, and play an important role in the GVL effect
post CBT. We previously demonstrated the ability to ex-vivo expand
CB into NK subsets with profound NK in-vitro and in-vivo cytotoxic
activity (Ayello/Cairo BBMT 2006). We further observed differen-
tial protein profiling in CB vs PB CD56dim, in which NKG2A was
overexpressed (Shereck/Cairo, ASH 2007; ASPHO 2007; AACR
2007). The differential proteins also included IP3R type 3, NCR3,
MAPKAPK5, Notch 2, PLEK, and NF-X1. In this report, we com-
pared the genomic expression pattern in CB vs PB CD56dim. CB and
PB NK cells were isolated indirectly by magnetic separation from
non-NK cells. Then, the CD561 CD161 NK cells (CD56dim)
were selected with CD16 (FCGR3) MicroBeads. For genomic stud-
ies, total RNA was isolated and reverse transcribed to cDNA using
T7-Oligo (dT) primer. cRNA was Biotin-labeled by in vitro tran-
scription. Fragmented biotin-labeled cRNA was hybridized to Gen-
eChip U133A_2 (Affymetrix). Data were analyzed using Agilent
GeneSpring. Signal intensities were compared using one way AN-
OVA and Welch Test for statistical analysis. There were 193 and
222 genes over and under expressed at the genomic level between
CB vs PB CD56dim NK cells, respectively. CB vs PB CD56dim signif-
icantly overexpressed NKG2A (2.14F), CD16b (2.46F), KIR2D
(2.13F), NKp44 (NCR2; 2.62F), PBX1 (4.29F), ENPEP (3.93F).
There was no significant difference in NKR gene expression of
CD16a, CD161, NKG2C, and NKp46 in CB vs PB CD56dim. CB
vs PB CD56dim underexpressed IP3R (1.32F), MAPKAPK5
(1.77F), NCR3 (1.24F), ACACB (3.23F), BBS1 (2.00F). These re-
sults suggest that NKR protein product levels in CB CD56dim may
be directly regulated at the translation level. The differential gene ex-
pression of IP3R, ENPEP, PBX1, and MAPKAPK5 between CB vs
PB suggests the involvements of IP3 and calcium ions in NKR signal-
ing pathways. The potential regulators of this process may include
PBX1, ENPEP, ACACB, and BBS1. We conclude that genomic dif-
ferences between CB vs PB CD56dim may play an important role in
regulating NKR signaling pathway, and thus contribute to disparate
cytotoxic activity between CB vs PB and suggest a possible explana-
tion for immaturity of cord blood innate and adaptive immunity.
(The first two authors contributed equally.)392
HUMAN HERPES VIRUS TYPE 6 REACTIVATION AFTER HAEMATOPOIETIC
STEM CELL TRANSPLANTATION: SUPERIOR SPECIFIC HHV6 T-CELL RE-
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Objective: Haematopoietic stem cell transplantation (HSCT) is
frequently complicated by early Human herpesvirus type 6
(HHV6) reactivation and is associated with poor survival and severe
acute Graft-versus-host-disease (aGvHD). We hypothesized that
HHV6 may be a trigger for immunedysregulation, resulting in allor-
eactivity. We investigated total T-cell numbers and HHV6-specific
Interferon-g (IFNg) producing T-cells in children with or without
HHV6-reactivation after HSCT using a newly developed enzyme-
linked immunospot (ELISPOT) technique.
Methods: Prospectively, HHV6, Cytomegalovirus, Adenovirus
and Epstein Barr virus DNA-loads were weekly monitored by quan-
titative realtime-PCR and clinical data were collected. HHV6 reac-
tivation was defined as HHV6 DNA-load .250cp/mL. T-cell
reconstitution was prospectively measured every other week by im-
munophenotyping (markers CD3, CD4 and CD8). Numbers of
IFNg-producing T-cells in PBMCs were retrospectively determined
by ELISPOT after overnight stimulation with HHV6-virus lysate
(ABI, Columbia, Maryland, USA) 2 months after HSCT.
Results: Twenty-one HSCT patients were analyzed (median age
4.4 years; range 1–16.5yrs). Within the first two months, 13/21
(62%) patients developed HHV6 reactivation; median time of reacti-
vation was 14 (range 1–41) days. The development of other virusreac-
tivations did not differ between the two groups; 4/13 versus 3/8
respectively. The median number of IFNg-producing specific
HHV6 T-cells 2 months after HSCT was significantly increased in
the patients with HHV6-reactivation; 40 (0–362) versus 0 (0–25) spe-
cific T-cells per million PBMCs (p5 0.006). Additionally, the median
CD31 T-cell numbers were significantly increased in these patients;
393 (32–5514) versus 93 (0–641) T-cells/uL (p5 0.03), including me-
dian CD81 T-cells; 79% (6–87 %) versus 33% (0–83%) (p5 0.03).
Conclusions: Patients with HHV6 reactivation had significantly
higher numbers of IFNg-producing HHV6-specific T-cells and
more CD31T-cells/uL, among which mainly CD81T-cells. Given
the association of HHV6 reactivation and aGvHD, these T-cells
may be alloreactive.393
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Background: Haematopoietic stem cell transplantation (HSCT)
is frequently complicated by human herpesvirus 6 (HHV6), cyto-
megalovirus (CMV) or Epstein Barr virus (EBV) reactivations. Her-
pesvirusreactivations are associated with severe morbidity and
mortality after HSCT. Although T-lymphocytes play an important
role in the clearance of viral reactivations after HSCT, an easy mea-
sure of potent T-cell responses for predicting outcome of viral reac-
tivations is lacking. We analyzed expression of perforin (a cytolytic
pore-forming protein) as a marker for cytotoxic potential in
CD81T-cells in children and related this to the clearance of viral re-
activations after HSCT.
Methods: In a prospective cohortstudy (2007–2008), we weekly
monitored HHV6, CMV and EBV DNA loads in plasma after
HSCT by quantitative realtime PCR. Herpesvirus reactivation was
defined as DNA load .1000 cp/mL. CMV- and EBVreactivation
were treated according to local guidelines. HHV6reactivation was
treated when there was clinical suspicion of disease. We have weekly
analyzed Perforin expression in CD81T-cells by whole blood FAC-
Sanalysis, until 4 months after HSCT.
Results: A total of 27 patients were included with a median age of
4.3 (range 0.3–20.1) years. 15/27 (56%) recipients received bone-
marrow (7/15 from matched family donors) or unrelated peripheral
blood stemcells while 12/27 (44%) recipients received unrelated
cordblood stemcells. All patients received myeloablative condition-
ing and standardized Graft-versus-host disease prophylaxis. During
the first 4 months after HSCT, 16 patients developed HHV6reacti-
vation, 2 patients developed CMVreactivation and 1 patient devel-oped EBVreactivation. The median time of herpesvirusreactivation
peak was 2.4 weeks (range 1.3–15.6) after HSCT. Viral clearance
was marked by a perforin peak in CD81 T-cells; median time of
maximum perforin expression in CD81T-cells was 4 weeks (range
1.4–15.9) after HSCT. Patients with herpesvirusreactivation
(HHV6, CMV or EBV) showed significantly higher perforin-expres-
sion in CD81T-cells during viral load clearance than patients with-
out herpesvirusreactivation (17.2% (range 0–63%) versus 6.8%
(range 0–16%); p 5 0.003).
Conclusion: Herpesvirus reactivation clearance was significantly
associated with a peak in perforin-expressing CD81T-cells. Al-
though virus-specific immune responses after HSCT have to be elu-
cidated, perforin expression in T-cells is a useful marker for antiviral
T-cell responses and viral load clearance after HSCT.
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NK cells play a significant role in tumor cell recognition and cyto-
toxicity (Trinchieri et al Adv Immunol, 1990). NKG2D-mediated
recognition of malignant cells by NK cells is enabled through the tu-
mor-associated expression of NKG2DL. Among these NKG2DL,
MIC A and B are significantly expressed on epithelial compared to
hematological tumors (Bauer et al Science, 1999). Skov et al (Cancer
Res, 2005) demonstrated a significant increase in surface expression
of MIC A and B in various epithelial cancer cell lines after exposure
to HDACi. We compared the expression of NKG2DL MIC A and B
in common pediatric hematological tumor cell lines and the impact
of enhanced expression of NKG2DL on NK cell mediated cytotox-
icity. Cell lines used were: ALL (SUP-B15, RS 4:11, REH, Jurkat),
NHL (Toledo, Ramos). Cells were co-cultured for 24hrs with 0, 5
and 10ng/ml of Romidepsin. MICA/B PE antibody was used for
flow cytometry staining. Purified adult peripheral blood NK
(CD561/3-) cells and IL-2 activated NK cells (12hr incubation)
were added to target cells (cultured with 5–10ng/ml of Romidepsin
x 24hrs) at effector to target ratio of 5:1 and 10:1 and incubated
for 2hrs. NK cell cytotoxicity was determined by a standard euro-
pium assay. There was a significant increase in expression of
MICA/B in ALL cell lines when co-cultured with Romidepsin at
10ng/ml (RS 4:11 0.2% vs 19.2% p\0.0001, REH 0.2% vs 46%
p 5 0.0003, Jurkat 1.12% vs 44.7% p\0.0001). We also noted sig-
nificant increase in MICA/B in some NHL cell lines when co-
cultured with Romidepsin at 10ng/ml (Toledo [DLBCL] 0.5% vs
15.8% p5 0.0001, Ramos [BL] 0.57% vs 33.6% p5 0.0003). There
was significant increase in vitro cytotoxicty in RS 4:11 cells at E:T
ratio of 5:1 and 10:1 (5:1 specific release: RS 4:11 cells1NK cells
vs. RS 4:11 cells1IL-2 activated NK cells vs. RS 4:11 cells1NK cells
with 10ng/ml of Romidepsin vs. RS 4:11 cells1IL-2 activated NK
cells with 10ng/ml of Romidepsin was 3.3% vs 6% vs 45% vs
61.6% p\0.01, and at 10:1 ratio 9.3% vs 10.6% vs 71.6% vs
86.3% p\0.05, respectively). In summary, these results suggest
that Romidepsin induces significant expression of MICA/B ligands,
enhancing their susceptibility for NKG2D-mediated cytotoxicity by
NK cells. The combination of Romidepsin and NK cells presents
a potential for ACI. Future studies will be conducted with MIC A
and B antibodies to determine the specificity of the Romidepsin ef-
fect and the invivo cytotoxicity in a human/mouse xenograft SCID
model.395
ABSOLUTE LYMPHOCYTE COUNT AT DAY 30 PREDICTS SURVIVAL IN RE-
CIPIENTS OF A T CELL DEPLETED ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
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